The dynamics of soluble Fas/APO 1 apoptotic biochemical marker in acute ischemic stroke patients

Mukherjee, 2011, Epidemiology and the global burden of stroke, World Neurosurg, 76, S85, 10.1016/j.wneu.2011.07.023 Turley, 2005, Molecular mechanisms in the pathogenesis and treatment of acute ischemic stroke, J Invest Surg, 18, 207, 10.1080/08941930591004449 Hirt, 2005, [Cerebral ischemia and apoptosis], Rev Med Suisse, 1, 1149 Mergenthaler, 2004, Pathophysiology of stroke: lessons from animal models, Metab Brain Dis, 19, 151, 10.1023/B:MEBR.0000043966.46964.e6 Broughton, 2009, Apoptotic mechanisms after cerebral ischemia, Stroke, 40, e331, 10.1161/STROKEAHA.108.531632 Dirnagl, 1999, Pathobiology of ischaemic stroke: an integrated view, Trends Neurosci, 22, 391, 10.1016/S0166-2236(99)01401-0 Barbosa, 2010, Increased SOD1 association with chromatin, DNA damage, p53 activation, and apoptosis in a cellular model of SOD1-linked ALS, Biochim Biophys Acta, 1802, 462, 10.1016/j.bbadis.2010.01.011 Genc, 2009, TNF-related apoptosis-inducing ligand in Alzheimer's disease, Neurol Sci, 30, 263, 10.1007/s10072-009-0047-5 Blandini, 2003, Effects of dopaminergic stimulation on peripheral markers of apoptosis: relevance to Parkinson's disease, Neurol Sci, 24, 157, 10.1007/s10072-003-0107-1 Linnik, 1993, Evidence supporting a role for programmed cell death in focal cerebral ischemia in rats, Stroke, 24, 2002, 10.1161/01.STR.24.12.2002 Linnik, 1995, Apoptotic DNA fragmentation in the rat cerebral cortex induced by permanent middle cerebral artery occlusion, Brain Res Mol Brain Res, 32, 116, 10.1016/0169-328X(95)00069-5 Endres, 1998, Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family, J Cereb Blood Flow Metab, 18, 238, 10.1097/00004647-199803000-00002 Thornberry, 1998, Caspases: enemies within, Science, 281, 1312, 10.1126/science.281.5381.1312 Cryns, 1998, Proteases to die for, Genes Dev, 12, 1551, 10.1101/gad.12.11.1551 Wallach, 1999, Tumor necrosis factor receptor and Fas signaling mechanisms, Annu Rev Immunol, 17, 331, 10.1146/annurev.immunol.17.1.331 Yuan, 1997, Transducing signals of life and death, Curr Opin Cell Biol, 9, 247, 10.1016/S0955-0674(97)80069-5 Nagata, 1995, The Fas death factor, Science, 267, 1449, 10.1126/science.7533326 Mahovic-Lakusic, 2001, Cerebrospinal fluid level of soluble Fas/APO-1 in acute stroke patients - preliminary report [abstract], J Neurol Sci, 187, S248 Rosenbaum, 2000, Fas (CD95/APO-1) plays a role in the pathophysiology of focal cerebral ischemia, J Neurosci Res, 61, 686, 10.1002/1097-4547(20000915)61:6<686::AID-JNR12>3.0.CO;2-7 Cheng, 1994, Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule, Science, 263, 1759, 10.1126/science.7510905 Ackery, 2006, Inhibition of Fas-mediated apoptosis through admininstration of soluble Fas receptor improves functional outcome and reduces posttraumatic axonal degeneration after acute spinal cord injury, J Neurotrauma, 23, 604, 10.1089/neu.2006.23.604 Tarkowski, 1999, Intrathecal expression of proteins regulating apoptosis in acute stroke, Stroke, 30, 321, 10.1161/01.STR.30.2.321 Cascino, 1995, Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing, J Immunol, 154, 2706, 10.4049/jimmunol.154.6.2706 Lenzlinger, 2002, Prolonged intrathecal release of soluble Fas following severe traumatic brain injury in humans, J Neuroimmunol, 122, 167, 10.1016/S0165-5728(01)00466-0 Ohtsuka, 1999, Clinical implications of circulating soluble Fas and Fas ligand in patients with acute myocardial infarction, Coron Artery Dis, 10, 221, 10.1097/00019501-199906000-00003 Boylan, 2001, Serum and cerebrospinal fluid soluble Fas levels in clinical subgroups of multiple sclerosis, Immunol Lett, 78, 183, 10.1016/S0165-2478(01)00244-9